Business Context and Reporting Period
This Form 8-K filing by CRISPR Therapeutics AG covers events occurring between November 10, 2017, and November 13, 2017. The company, incorporated in Switzerland, reported the appointment of a new Chief Financial Officer and announced strategic developments regarding its therapeutic portfolio and collaborations.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on executive compensation and corporate events.
Material Changes and Executive Appointment
On November 13, 2017, the Company appointed Michael J. Tomsicek as Senior Vice President and Chief Financial Officer, effective immediately. Mr. Tomsicek previously served as CFO at Abiomed, Inc., and held various financial leadership roles at Cubist Pharmaceuticals and GE Healthcare.
Compensation Arrangements
- Base Salary: $380,000 annually.
- Target Bonus: 40% of base salary (pro-rated for 2017).
- Equity Award: One-time grant of options to purchase 180,000 common shares. Vesting schedule: 25% on November 13, 2018, and the remaining 75% ratably monthly over three years.
- Sign-on Payment: One-time payment of $50,000, subject to forfeiture if employment terminates within the first year.
- Termination Provisions: Six-month notice period for termination without Cause or resignation for Good Reason. In the event of a Change in Control followed by termination within 12 months, the notice period extends to 12 months with full acceleration of equity awards.
Strategic Developments
- November 10, 2017: Announced new additions to its portfolio of allogeneic CRISPR-based CAR-T therapies at the SITC Annual Meeting.
- November 13, 2017: Announced a collaboration with CureVac and Casebia regarding mRNA for gene-editing programs.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, forward-looking revenue projections, or specific risk factors beyond standard employment agreement contingencies. The document highlights the company's focus on expanding its gene-editing therapeutic pipeline through internal development and external partnerships.
Investor Verification Checklist
- Verify the vesting schedule and performance conditions of the 180,000 stock options granted to the new CFO.
- Review the full text of the press releases (Exhibits 99.2 and 99.3) for details on the CAR-T therapy portfolio additions and the CureVac/Casebia collaboration terms.
- Confirm the impact of the new CFO's appointment on the company's financial reporting and strategic direction in subsequent quarterly filings.
- Monitor future filings for any changes to the employment agreement or acceleration of equity awards in the event of a Change in Control.